Abstract
The combination of ivosidenib — an inhibitor of mutant isocitrate dehydrogenase 1 (IDH1) — and azacitidine showed encouraging clinical activity in a phase 1b trial involving patients with newly dia...
Cite
CITATION STYLE
APA
Montesinos, P., Recher, C., Vives, S., Zarzycka, E., Wang, J., Bertani, G., … Döhner, H. (2022). Ivosidenib and Azacitidine in IDH1 -Mutated Acute Myeloid Leukemia. New England Journal of Medicine, 386(16), 1519–1531. https://doi.org/10.1056/nejmoa2117344
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free